In short
Recurrent angiosarcoma is a highly aggressive cancer that returns after initial treatment, presenting one of the most challenging situations in cancer care. Understanding the nature of recurrence and available treatment options can help patients and their families navigate this difficult diagnosis.
What Is Recurrent Angiosarcoma?
Recurrent angiosarcoma refers to cancer that has come back after treatment. This cancer originates in the cells that line blood vessels or lymphatic vessels and is known for its tendency to return even after seemingly successful treatment. Angiosarcoma is a rare and highly aggressive type of soft tissue sarcoma, a cancer that develops in the tissues connecting and supporting the body.
When angiosarcoma recurs, it may come back in the same location where it first appeared, known as local recurrence. It can also return in nearby tissues or spread to distant parts of the body such as the lungs, liver, or bones.
Rates and Patterns of Recurrence
Angiosarcoma has a very high rate of recurrence compared to other cancers. The majority of recurrences happen within the first two years after initial treatment. Studies show that approximately 75% of cases that recur do so within 24 months of local treatment.
Angiosarcomas affecting the scalp and face are particularly prone to recurrence. In one reported case, a patient experienced recurrent scalp angiosarcoma four times despite undergoing surgery each time. This high recurrence rate is partly due to the infiltrative nature of these tumors, which makes it difficult to remove all cancer cells during surgery.
The cancer can spread quickly to other parts of the body. Between 16% and 44% of patients already have advanced or metastatic disease (cancer that has spread to distant organs) at the time of initial diagnosis.
Recognizing Recurrent Disease
The symptoms of recurrent angiosarcoma depend on where the cancer returns. If the cancer comes back in the same area where it first appeared, particularly on the skin, patients may notice similar warning signs to their initial diagnosis.
For skin recurrences, especially on the head, neck, or scalp, symptoms may include a bruise-like area that grows larger over time, a raised reddish or purple bump, or a sore that bleeds when scratched or bumped.
When angiosarcoma recurs in internal organs or spreads to distant sites, symptoms can be less specific. These may include persistent fatigue, unexplained weight loss, pain near the affected area, or symptoms related to the specific organ involved.
Treatment Options for Recurrent Angiosarcoma
Surgery
For recurrent angiosarcoma, surgery remains an important treatment option when the cancer has returned to a localized area. Surgeons aim to remove the tumor along with a margin of healthy tissue to ensure all cancer cells are eliminated.
However, achieving clear margins can be challenging with recurrent disease. In cases where the cancer has spread throughout a limb, partial or complete amputation may be necessary to stop the cancer, although surgeons generally try to perform limb-sparing surgery when possible.
Radiation Therapy and Chemotherapy
A major challenge in treating recurrent angiosarcoma is that some patients, particularly those with radiation-induced angiosarcoma, have already received radiation therapy for a previous cancer. This limits how much additional radiation can be safely given.
Studies suggest that patients who receive a combination of treatments after surgery, including radiotherapy and chemotherapy, may have better outcomes than those treated with surgery alone. One case report noted that a patient who underwent surgery four times for recurrent scalp angiosarcoma but never received radiotherapy or chemotherapy continued to experience recurrences.
Chemotherapy uses drugs to destroy cancer cells and is a main treatment option for metastatic angiosarcoma. The most commonly used chemotherapy drugs include paclitaxel, which is given weekly, and combinations containing doxorubicin or gemcitabine. One patient with recurrent scalp angiosarcoma achieved long-term survival using combination chemotherapy with cyclophosphamide, epirubicin, vincristine, and dacarbazine.
Targeted Therapies and Immunotherapy
Targeted therapy refers to treatments that specifically attack cancer cells based on their genetic characteristics. For recurrent angiosarcoma, targeted medicines such as pazopanib, which blocks blood vessel formation, have shown promise in some patients.
Immunotherapy is an emerging treatment that helps the patient's own immune system fight cancer. One remarkable case involved a 63-year-old man with recurrent angiosarcoma affecting his face and liver who was treated with pembrolizumab, an immunotherapy drug that targets a protein called PD-1. After 13 cycles of treatment, his liver disease shrank significantly and he had no new facial lesions. Eight months after stopping therapy, he had developed no new or progressive disease.
Multidisciplinary Approach
The best outcomes for recurrent angiosarcoma typically come from a comprehensive approach that may combine surgery, radiation therapy, chemotherapy, or immunotherapy. This requires coordination among different specialists including surgeons, medical oncologists (doctors who specialize in cancer treatment with drugs), and radiation oncologists (doctors who specialize in radiation treatment).
Prognosis and Survival
The outlook for recurrent angiosarcoma is generally poor, but varies depending on several factors. The overall survival for patients with advanced or metastatic disease ranges from 6 to 16 months.
However, there are reports of patients achieving longer survival times with comprehensive treatment. One patient with scalp angiosarcoma and multiple metastases achieved an overall survival of 38 months after initial diagnosis through combination therapy including multiple chemotherapy agents and radiotherapy.
Factors associated with worse outcomes include the presence of metastatic disease, increasing age, tumor location on the scalp or neck, tumor size greater than 5 centimeters, and the presence of multiple skin lesions.
Patients who can undergo surgery to completely remove recurrent disease with clear margins generally have better outcomes than those whose tumors cannot be fully removed.
